As the market gears up for tomorrow's opening, all eyes are on a line-up of prominent companies set to reveal their latest earnings. Abbott Laboratories (ABT, Financial) is expected to report earnings per share (EPS) of $1.07, reflecting investors' keen focus on the healthcare giant's performance.
Joining Abbott, U.S. Bancorp (USB) will disclose its financial results, with analysts predicting an EPS of $0.98. This release is particularly watched by investors following the bank's strategic moves in the current economic environment.
Travelers Companies, Inc. (TRV), a leader in the insurance sector, is anticipated to announce an EPS of $0.80. The market is eager to understand how Travelers has navigated recent industry challenges.
Additionally, Citizens Financial Group, Inc. (CFG) is slated to report an EPS of $0.75. Stakeholders will be evaluating the bank’s performance amid prevailing financial sector dynamics.
These earnings reports are highly anticipated as they will provide insights into the companies' operational successes and challenges in the prevailing economic conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $136.76 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 7.87% from the current price of $126.79. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 6.61% from the current price of $126.79. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
